查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球胰島素輸送設備市場：按類型、最終用戶劃分 - 預測（~2028 年）
市場調查報告書
商品編碼
1324796

全球胰島素輸送設備市場：按類型、最終用戶劃分 - 預測（~2028 年）

Insulin Delivery Devices Market by Type (Insulin Pens [Reusable, Disposable], Insulin Pumps (Tethered, Tubeless), Insulin Syringes, Insulin Pen Needles (Standard, Safety)), End User (Hospitals & Clinics, Patients/Homecare) - Global Forecast to 2028
出版日期: | 出版商: MarketsandMarkets | 英文 230 Pages | 訂單完成後即時交付

價格
簡介目錄

全球胰島素輸送設備市場規模預計將從 2023 年的 308 億美元增至 2028 年的 462 億美元，預測期內復合年增長率為 8.5%。

市場增長主要受到糖尿病人口增加、政府支持和有利的報銷計劃以及胰島素輸送設備技術進步等因素的推動。另一方面，發展中國家胰島素輸送裝置系統的高成本和缺乏報銷可能會在一定程度上限制市場發展。

預計胰島素泵細分市場在預測期內將以最高複合年增長率增長。

按最終用戶劃分，患者/家庭護理最終用戶細分市場預計在預測期內將以最高複合年增長率增長。這主要是由於人們對糖尿病護理設備的認識提高、糖尿病醫療保健支出增加以及有利的報銷，從而提高了患者對家庭護理的接受度。

按地區劃分，北美預計將佔據最大的市場份額。

2022 年，北美佔據市場主導地位。聯網糖尿病管理設備的增長、糖尿病人口的增加、對先進技術產品的需求、政府舉措以及該地區糖尿病自我管理意識的提高是主導市場的關鍵因素。

本報告研究和分析了全球胰島素輸送設備市場，提供了關鍵驅動因素和限制因素、競爭格局和未來趨勢等信息。

目錄

第 1 章 簡介

第二章研究方法論

第三章執行摘要

第四章 主要考慮因素

  • 胰島素輸送裝置：市場概覽
  • 亞太地區：胰島素輸送設備市場，按類型和國家/地區劃分（2022 年）
  • 胰島素輸送設備市場：地域組合
  • 胰島素輸送設備市場：區域組合（2023-2028）
  • 胰島素輸送裝置市場：發達國家與發展中國家市場

第五章市場概況

  • 介紹
  • 市場動態
    • 促進者
    • 抑製劑
    • 機會
    • 任務
  • 波特五力分析
  • 監管分析
    • 北美
    • 歐洲
    • 亞太地區
    • 其他地區
  • 行業洞察
  • 贖回場景
    • 美國
    • 加拿大
    • 英國
    • 澳大利亞
    • 其他國家
  • 技術分析
  • 主要會議和活動（2023-2024）
  • 價格分析
  • 專利分析
  • 價值鏈分析
  • 生態系統市場地圖
  • 使用案例
  • 主要利益相關者和採購標準

第六章胰島素輸送設備市場：按類型

  • 介紹
  • 胰島素筆
  • 胰島素泵
  • 胰島素筆針
  • 胰島素注射器
  • 其他胰島素輸送裝置

第七章胰島素輸送設備市場：按最終用戶分類

  • 介紹
  • 病人/家庭護理
  • 醫院、診所

第八章胰島素輸送設備市場：按地區

  • 介紹
  • 北美
    • 北美：經濟衰退的影響
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲：經濟衰退的影響
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 亞太地區：經濟衰退的影響
    • 日本
    • 中國
    • 印度
    • 亞太其他地區
  • 其他地區

第9章 競爭格局

  • 概述
  • 領先企業採用的致勝方法
  • 市場份額分析
  • 市場主要參與者的收入份額分析
  • 市場排名分析
  • 公司評級象限：主要公司
  • 公司評級象限：初創企業、中小企業
  • 公司在胰島素輸送設備市場的足跡
    • 類型足跡
    • 區域足跡
  • 競爭情景

第十章公司簡介

  • 大公司
    • EMBECTA CORP.（前身為 BECTON、DICKINSON 及公司糖尿病護理業務）
    • NOVO NORDISK A/S
    • MEDTRONIC PLC
    • SANOFI
    • LILLY
    • YPSOMED HOLDING AG
    • TANDEM DIABETES CARE, INC.
    • INSULET CORPORATION
    • BIOCON LIMITED
    • ROCHE DIABETES CARE
    • OWEN MUMFORD
    • MEDTRUM TECHNOLOGIES INC.
    • TERUMO CORPORATION
    • WOCKHARDT
  • 其他公司
    • CEQUR CORPORATION
    • EOFLOW CO., LTD.
    • HINDUSTAN SYRINGES & MEDICAL DEVICES LTD
    • SOOIL DEVELOPMENTS CO., LTD
    • SUNGSHIM MEDICAL CO., LTD.
    • VICENTRA B.V.
    • DEBIOTECH SA
    • JIANGSU DELFU MEDICAL DEVICE CO., LTD
    • HASELMEIER
    • MANNKIND CORPORATION
    • HTL-STREFA S.A.

第十一章附錄

簡介目錄
Product Code: MD 5192

The global insulin delivery devices market is projected to reach USD 46.2 billion by 2028 from USD 30.8 billion in 2023, at a CAGR of 8.5% during the forecast period. Growth in the insulin delivery devices market is mainly driven by factors such as the growing prevalence of diabetic population, government support and favorable reimbursement schemes, technological advancements in insulin delivery devices. On the other hand, the high costs and lack of reimbursements in developing countries of insulin delivery devices systems are expected to restrain market growth to a certain extent.

Insulin pumps segment is projected to grow at the highest CAGR during the forecast period By type, the global insulin delivery devices market is segmented into insulin pens, insulin pumps, insulin pen needles, insulin syringes and other insulin delivery devices which includes, transdermal insulin patch, insulin jet injectors, insulin inhalers. The insulin pump segment is further sub-segmented into tethered insulin pumps and tubeless insulin pumps. As newer and more refined technology has now revolutionized insulin pumps in terms of their quality of care, and ease of use resulting in improved glycemic control, in addition favourable reimbursement in developed countries is contributing towards the adoption of these devices as a result this segment is projected to have the highest CAGR in the forecast period.

Patients/Homecare end user segment is projected to grow at the highest CAGR during the forecast period By end users, the insulin delivery devices market is segmented into patients/ homecare and hospitals & clinics. The patients/home care segment is expected to grow at the highest CAGR during the forecast period. This is primarily attributed to the rising patient acceptance of home care as a result of growing awareness of diabetes care devices, increasing diabetic healthcare expenditure and favourable reimbursements.

By region, North America is projected to account for the largest share of the insulin delivery devices market

Based on region, the insulin delivery devices market is segmented into North America, Europe, Asia Pacific, and Rest of the World. North America dominated the insulin delivery devices market in 2022. The growth of connected diabetes management devices, the rising diabetic population, demand for technologically advanced products, government initiatives, and increasing awareness of self-diabetes management in the region are the main factors driving North America to dominate the insulin delivery devices market.

Breakdown of supply-side primary interviews: * By Company Type: Tier 1 - 46%, Tier 2 - 33%, and Tier 3 - 21% * By Designation: C-level - 43%, Director-level - 35%, and Others - 22% * By Region: North America - 34%, Europe - 26%, APAC -19%, Rest of World-21%

The prominent players operating in the global insulin delivery devices market are Embecta Corp. (Formely Becton, Dickinson and Company Diabetes Care Business (US), Ypsomed Holding AG (Switzerland), Tandem Diabetes Care (US), Insulet Corporation (US), Biocon Limited (India), Novo Nordisk A/S (Denmark), Medtronic (Ireland), Sanofi (France), Eli Lilly and Company (US), Roche Diabetes Care (Switzerland), Owen Mumford (England), Mrdtrum Technologies Inc. (China), Terumo Corporation (Japan), Wockhardt (India), Cerur Corporation (Switzerland), EoFlow CO., Ltd. (South Korea), Hindustan Syringes & Medical Devices Ltd (India), Sooil Developments CO., Ltd (Korea), Sungshim Medical Co., Ltd. (South Korea), Vicentra B.V. (Netherland), Debiotech SA (Switzerland), Jiangsu Delfu Medical Device Co., Ltd (China), Haselmeier (Germany), Mannkind Corporation (US), HTL-Sterfa S.A. (Poland).

Research Coverage

This report studies the insulin delivery devices market based on type, application, product, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to four main regions and respective countries.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:

  • Analysis of key drivers (growing prevalence of diabetic population, technological advancements in insulin delivery devices, government support and favourable reimbursement schemes to favour market growth), restraints (high cost and lack of reimbursement in developing countries, needle anxiety in patients to affect the growth of the pen needles and syringes market, oral insulin as an alternative drug delivery method), opportunities (increasing research and development activities and strategic partnerships, advances in syringe and technology) and challenges (Needle stick injuries and misuse of injection pens)
  • Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new product launches in the global insulin delivery devices market
  • Market Development: Comprehensive information on the lucrative emerging markets by type, end user, and region.
  • Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global insulin delivery devices market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global insulin delivery devices market. This report also helps stakeholders understand the pulse of the molecular quality controls market and provides them information on key market drivers, restraints, challenges, and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 INSULIN DELIVERY DEVICES MARKET: RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 PRIMARY SOURCES
      • 2.1.2.1 Key data from primary sources
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2022)
    • FIGURE 6 MARKET SIZE ESTIMATION: COMPANY-WISE REVENUE SHARE ANALYSIS (2022)
    • FIGURE 7 INSULIN DELIVERY DEVICES MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2023-2028)
    • FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS OF INSULIN DELIVERY DEVICES MARKET
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 9 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET SHARE ESTIMATION
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 IMPACT OF RECESSION
    • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS. 2021-2027 (%GROWTH)

3 EXECUTIVE SUMMARY

    • FIGURE 10 INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 11 INSULIN DELIVERY DEVICES MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 GEOGRAPHICAL SNAPSHOT OF INSULIN DELIVERY DEVICES MARKET

4 PREMIUM INSIGHTS

  • 4.1 INSULIN DELIVERY DEVICES: MARKET OVERVIEW
    • FIGURE 13 INCREASING TECHNOLOGICAL ADVANCEMENTS IN INSULIN DELIVERY DEVICES TO DRIVE MARKET
  • 4.2 ASIA PACIFIC: INSULIN DELIVERY DEVICES MARKET, BY TYPE AND COUNTRY (2022)
    • FIGURE 14 INSULIN PENS SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2022
  • 4.3 INSULIN DELIVERY DEVICES MARKET: GEOGRAPHICAL MIX
    • FIGURE 15 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
  • 4.4 INSULIN DELIVERY DEVICES MARKET: REGIONAL MIX (2023-2028)
    • FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD (2023-2028)
  • 4.5 INSULIN DELIVERY DEVICES MARKET: DEVELOPED VS. DEVELOPING MARKETS
    • FIGURE 17 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 18 INSULIN DELIVERY DEVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing prevalence of diabetic population
    • FIGURE 19 GLOBAL PREVALENCE OF DIABETES IN INDIVIDUALS AGED 20-79 YEARS, 2015-2021 (MILLIONS)
    • FIGURE 20 PROJECTION OF DIABETES FOR INDIVIDUALS AGED 20-79 YEARS, 2030-2045 (MILLIONS)
    • FIGURE 21 TOP TEN COUNTRIES WITH HIGHEST COUNT OF DIABETICS (20-79 YEARS), 2021 & 2045
      • 5.2.1.2 Technological advancements in insulin delivery devices
    • FIGURE 22 ADVANCEMENTS IN INSULIN DELIVERY DEVICES
      • 5.2.1.3 Government support and favorable reimbursement schemes to favor market growth
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High costs and lack of reimbursement in developing countries
      • 5.2.2.2 Needle anxiety in patients to affect growth of pen needles and syringes market
      • 5.2.2.3 Oral insulin as alternative drug delivery method
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increasing R&D activities and strategic partnerships
      • 5.2.3.2 Increasing healthcare expenditure on diabetes care
    • FIGURE 23 TOTAL HEALTH EXPENDITURE ON DIABETES CARE, 2021-2045 (USD BILLION)
      • 5.2.3.3 Advances in syringe and needle technology
      • 5.2.3.4 Mandates pertaining to safety-engineered medical needles to encourage market growth
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Needlestick injuries and misuse of injection pens
      • 5.2.4.2 Lack of interoperability among insulin delivery devices
  • 5.3 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 2 INSULIN DELIVERY DEVICES MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.3.1 INTENSITY OF COMPETITIVE RIVALRY
    • 5.3.2 BARGAINING POWER OF SUPPLIERS
    • 5.3.3 BARGAINING POWER OF BUYERS
    • 5.3.4 THREAT OF SUBSTITUTES
    • 5.3.5 THREAT OF NEW ENTRANTS
  • 5.4 REGULATORY ANALYSIS
    • TABLE 3 INDICATIVE LIST OF REGULATORY AUTHORITIES
    • 5.4.1 NORTH AMERICA
      • 5.4.1.1 US
    • TABLE 4 US: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • FIGURE 24 FDA 510(K) APPROVAL PROCESS
      • 5.4.1.2 Canada
    • 5.4.2 EUROPE
    • FIGURE 25 CE MARK APPROVAL PROCESS FOR INSULIN DELIVERY DEVICES
    • 5.4.3 ASIA PACIFIC
      • 5.4.3.1 Japan
    • TABLE 5 JAPAN: CLASSIFICATION OF MEDICAL DEVICES AND REVIEWING BODY
      • 5.4.3.2 China
    • TABLE 6 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
      • 5.4.3.3 India
    • TABLE 7 INDIA: MEDICAL DEVICE CLASSIFICATION
      • 5.4.3.4 Australia
    • FIGURE 26 SUMMARY OF APPROVAL, ACCESS, AND DISTRIBUTION PATHWAYS FOR NEW TECHNOLOGY USED FOR INSULIN DRUG DELIVERY DEVICES
    • 5.4.4 REST OF THE WORLD
  • 5.5 INDUSTRY INSIGHTS
    • 5.5.1 GROWING DEMAND FOR HYBRID CLOSED-LOOP SYSTEMS/ARTIFICIAL PANCREAS DEVICE SYSTEMS
    • TABLE 8 HYBRID CLOSED-LOOP SYSTEMS: CURRENT MARKET SCENARIO
    • 5.5.2 SYNCHRONIZATION OF SMART INSULIN PENS WITH CGM SYSTEMS TO PROMOTE DIABETES DATA SHARING
    • TABLE 9 MAJOR SMART INSULIN PENS AVAILABLE GLOBALLY
    • 5.5.3 INCREASING NUMBER OF COLLABORATIONS AMONG STAKEHOLDERS
    • TABLE 10 INSULIN DELIVERY DEVICE MARKET: RECENT COLLABORATIONS
  • 5.6 REIMBURSEMENT SCENARIO
    • TABLE 11 INSULIN DELIVERY DEVICES: GLOBAL COVERAGE AND REIMBURSEMENT
    • 5.6.1 US
    • 5.6.2 CANADA
    • 5.6.3 UK
    • 5.6.4 AUSTRALIA
    • 5.6.5 OTHER COUNTRIES
  • 5.7 TECHNOLOGICAL ANALYSIS
  • 5.8 KEY CONFERENCES & EVENTS, 2023-2024
    • TABLE 12 INSULIN DELIVERY DEVICES MARKET: DETAILED LIST OF CONFERENCES & EVENTS
  • 5.9 PRICING ANALYSIS
    • 5.9.1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY PRODUCT
    • TABLE 13 AVERAGE SELLING PRICE OF INSULIN PENS, BY KEY PLAYER
    • TABLE 14 AVERAGE SELLING PRICE OF INSULIN PUMPS, BY KEY PLAYER
  • 5.10 PATENT ANALYSIS
    • FIGURE 27 PATENT PUBLICATION TRENDS (JANUARY 2011-MAY 2023)
    • 5.10.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
    • FIGURE 28 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTES) FOR INSULIN DELIVERY DEVICES PATENTS (JANUARY 2011-MAY 2023)
    • FIGURE 29 TOP APPLICANT COUNTRIES/REGIONS FOR INSULIN DELIVERY DEVICES (JANUARY 2011-MAY 2023)
  • 5.11 VALUE CHAIN ANALYSIS
    • FIGURE 30 INSULIN DELIVERY DEVICES MARKET: VALUE CHAIN ANALYSIS
  • 5.12 ECOSYSTEM MARKET MAP
    • FIGURE 31 INSULIN DELIVERY DEVICE MARKET: ECOSYSTEM MAPPING
  • 5.13 USE CASES
    • TABLE 15 T:SLIM X2 INSULIN PUMPS TO OFFER CONTINUED IMPROVEMENTS IN FUNCTIONALITY, SAFETY, AND WEARABILITY OF PUMPS
    • TABLE 16 AUTOMATED AND SMART INSULIN DELIVERY DEVICE FOR DIABETES CARE
    • TABLE 17 CONTRIBUTION OF SMART INSULIN PEN IN LIGHTENING DIABETES MANAGEMENT LOAD
  • 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF INSULIN DELIVERY DEVICES
    • 5.14.2 BUYING CRITERIA FOR INSULIN DELIVERY DEVICES
    • FIGURE 33 KEY BUYING CRITERIA FOR END USERS

6 INSULIN DELIVERY DEVICES MARKET, BY TYPE

  • 6.1 INTRODUCTION
    • TABLE 18 INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 19 INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021-2028 (THOUSAND UNITS)
  • 6.2 INSULIN PENS
    • 6.2.1 ADVANCED AND CONVENIENT SOLUTIONS FOR INSULIN ADMINISTRATION TO DRIVE MARKET
    • TABLE 20 INSULIN PENS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 21 INSULIN PENS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 22 INSULIN PENS MARKET, BY REGION, 2021-2028 (THOUSAND UNITS)
    • 6.2.2 REUSABLE INSULIN PENS
      • 6.2.2.1 Technology innovations to boost growth
    • TABLE 23 REUSABLE INSULIN PENS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.2.3 DISPOSABLE INSULIN PENS
      • 6.2.3.1 Shift toward eco-friendly environment to restrain growth of market during forecast period
    • TABLE 24 DISPOSABLE INSULIN PENS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3 INSULIN PUMPS
    • 6.3.1 NEWER AND MORE REFINED TECHNOLOGY TO DRIVE INSULIN PUMPS MARKET
    • TABLE 25 INSULIN PUMPS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 26 INSULIN PUMPS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 27 INSULIN PUMPS MARKET, BY REGION, 2021-2028 (THOUSAND UNITS)
    • 6.3.2 TETHERED INSULIN PUMPS
      • 6.3.2.1 Increasing collaborations and partnerships between companies to develop integrated CGM systems to drive market
    • TABLE 28 TETHERED INSULIN PUMPS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.3.3 TUBELESS INSULIN PUMPS
      • 6.3.3.1 Use of artificial intelligence and technological advancements to boost market
    • TABLE 29 TUBELESS INSULIN PUMPS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.4 INSULIN PEN NEEDLES
    • TABLE 30 INSULIN PEN NEEDLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 31 INSULIN PEN NEEDLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 32 INSULIN PEN NEEDLES MARKET, BY REGION, 2021-2028 (THOUSAND UNITS)
    • 6.4.1 STANDARD INSULIN PEN NEEDLES
      • 6.4.1.1 Affordability of standard insulin pen needles over safety pen needles to propel growth
    • TABLE 33 STANDARD INSULIN PEN NEEDLES OFFERED BY KEY PLAYERS
    • TABLE 34 STANDARD INSULIN PEN NEEDLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.4.2 SAFETY INSULIN PEN NEEDLES
      • 6.4.2.1 Reducing chances of infection and accidental pricking to drive market
    • TABLE 35 SAFETY INSULIN PEN NEEDLES OFFERED BY KEY PLAYERS
    • TABLE 36 SAFETY INSULIN PEN NEEDLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.5 INSULIN SYRINGES
    • 6.5.1 SAFETY CONCERNS AND INCREASING AWARENESS OF AFFORDABLE ALTERNATIVES TO RESTRAIN GROWTH
    • TABLE 37 INSULIN SYRINGES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 38 INSULIN SYRINGES MARKET, BY REGION, 2021-2028 (THOUSAND UNITS)
  • 6.6 OTHER INSULIN DELIVERY DEVICES
    • TABLE 39 OTHER INSULIN DELIVERY DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 40 OTHER INSULIN DELIVERY DEVICES MARKET, BY REGION, 2021-2028 (THOUSAND UNITS)

7 INSULIN DELIVERY DEVICES MARKET, BY END USER

  • 7.1 INTRODUCTION
    • TABLE 41 INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 7.2 PATIENTS/HOME CARE
    • 7.2.1 INCREASING AFFORDABILITY OF SELF-MONITORING SYSTEMS AND INSULIN DELIVERY DEVICES TO FUEL GROWTH
    • TABLE 42 INSULIN DELIVERY DEVICES MARKET FOR PATIENTS/HOME CARE, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 HOSPITALS & CLINICS
    • 7.3.1 RISING DEMAND FOR POINT-OF-CARE TESTING IN HOSPITALS TO BOOST MARKET
    • TABLE 43 INSULIN DELIVERY DEVICES MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021-2028 (USD MILLION)

8 INSULIN DELIVERY DEVICES MARKET, BY REGION

  • 8.1 INTRODUCTION
    • FIGURE 34 INSULIN DELIVERY DEVICES MARKET: GEOGRAPHIC SNAPSHOT
    • TABLE 44 INSULIN DELIVERY DEVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 8.2 NORTH AMERICA
    • 8.2.1 NORTH AMERICA: RECESSION IMPACT
    • FIGURE 35 NORTH AMERICA: INSULIN DELIVERY DEVICES MARKET SNAPSHOT
    • TABLE 45 NORTH AMERICA: INSULIN DELIVERY DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 46 NORTH AMERICA: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 47 NORTH AMERICA: INSULIN PENS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 48 NORTH AMERICA: INSULIN PUMPS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 49 NORTH AMERICA: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 50 NORTH AMERICA: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.2.2 US
      • 8.2.2.1 Rising prevalence of diabetes and favorable reimbursement scenario to drive market
      • 8.2.2.2 Growing venture capital investments and issuance of IPOs to propel market growth
    • TABLE 51 US: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 52 US: INSULIN PENS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 53 US: INSULIN PUMPS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 54 US: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 55 US: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.2.3 CANADA
      • 8.2.3.1 High prevalence of diabetes and favorable reimbursement for insulin delivery devices to boost market
    • TABLE 56 CANADA: ELIGIBILITY FOR INSULIN PUMPS AND SUPPLIES FOR TYPE I DIABETES, APRIL 2021
      • 8.2.3.2 Regulations for usage of safety-engineered needles to drive market
    • TABLE 57 CANADA: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 58 CANADA: INSULIN PENS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 59 CANADA: INSULIN PUMPS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 60 CANADA: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 61 CANADA: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.3 EUROPE
    • 8.3.1 EUROPE: RECESSION IMPACT
      • 8.3.1.1 EU's directive on prevention of sharps injuries in hospitals and healthcare sector to drive market
    • TABLE 62 EUROPE: INSULIN DELIVERY DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 63 EUROPE: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 64 EUROPE: INSULIN PENS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 65 EUROPE: INSULIN PUMPS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 66 EUROPE: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 67 EUROPE: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.3.2 GERMANY
      • 8.3.2.1 High prevalence of diabetes and favorable reimbursement for insulin devices to propel market
    • TABLE 68 GERMANY: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 69 GERMANY: INSULIN PENS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 70 GERMANY: INSULIN PUMPS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 71 GERMANY: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 72 GERMANY: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.3.3 UK
      • 8.3.3.1 Role of Diabetes UK in research and diabetes care to boost market
      • 8.3.3.2 Insulin pump penetration to boost market
    • TABLE 73 UK: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 74 UK: INSULIN PENS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 75 UK: INSULIN PUMPS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 76 UK: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 77 UK: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.3.4 FRANCE
      • 8.3.4.1 High insurance coverage and increasing affordability to drive market
    • TABLE 78 FRANCE: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 79 FRANCE: INSULIN PENS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 80 FRANCE: INSULIN PUMPS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 81 FRANCE: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 82 FRANCE: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.3.5 ITALY
      • 8.3.5.1 Regional variations in terms of coverage and benefits to hinder market growth
    • TABLE 83 ITALY: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 84 ITALY: INSULIN PENS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 85 ITALY: INSULIN PUMPS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 86 ITALY: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 87 ITALY: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.3.6 SPAIN
      • 8.3.6.1 Regulations for mandatory use of safety needles and increase in diabetic population to propel market
    • TABLE 88 SPAIN: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 89 SPAIN: INSULIN PENS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 90 SPAIN: INSULIN PUMPS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 91 SPAIN: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 92 SPAIN: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.3.7 REST OF EUROPE
      • 8.3.7.1 Strong presence of major insulin delivery device manufacturers to drive market
    • TABLE 93 INDICATIVE LIST OF COMPANIES HEADQUARTERED IN REST OF EUROPE
    • FIGURE 36 TOP FIVE COUNTRIES WITH HIGHEST NUMBER OF DIABETICS (20-79 YEARS) IN MILLIONS
    • TABLE 94 REST OF EUROPE: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 95 REST OF EUROPE: INSULIN PENS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 96 REST OF EUROPE: INSULIN PUMPS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 97 REST OF EUROPE: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 98 REST OF EUROPE: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.4 ASIA PACIFIC
    • 8.4.1 ASIA PACIFIC: RECESSION IMPACT
    • FIGURE 37 ASIA PACIFIC: INSULIN DELIVERY DEVICES MARKET SNAPSHOT
      • 8.4.1.1 High diabetes incidence and population in Asia Pacific to boost market
    • TABLE 99 ASIA PACIFIC: DIABETES PREVALENCE, BY COUNTRY
      • 8.4.1.2 Partnerships among global and local players in Asia Pacific to drive market
    • TABLE 100 ASIA PACIFIC: INSULIN DELIVERY DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 101 ASIA PACIFIC: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 102 ASIA PACIFIC: INSULIN PENS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 103 ASIA PACIFIC: INSULIN PUMPS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 104 ASIA PACIFIC: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 105 ASIA PACIFIC: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.4.2 JAPAN
      • 8.4.2.1 High adoption of insulin pens and approval of injectable insulin to propel growth
    • TABLE 106 JAPAN: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 107 JAPAN: INSULIN PENS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 108 JAPAN: INSULIN PUMPS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 109 JAPAN: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 110 JAPAN: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.4.3 CHINA
      • 8.4.3.1 Sharp increase in diabetes in past decade and government support to drive market
    • TABLE 111 CHINA: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 112 CHINA: INSULIN PENS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 113 CHINA: INSULIN PUMPS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 114 CHINA: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 115 CHINA: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.4.4 INDIA
      • 8.4.4.1 Government initiatives to promote domestic manufacture of medical devices to drive market
    • TABLE 116 INDIA: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 117 INDIA: INSULIN PENS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 118 INDIA: INSULIN PUMPS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 119 INDIA: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 120 INDIA: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.4.5 REST OF ASIA PACIFIC
      • 8.4.5.1 Vietnam: Large diabetic population to boost market
      • 8.4.5.2 Australia: Government initiatives to broaden patient access to diabetes products
    • TABLE 121 ASIA PACIFIC: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 122 ASIA PACIFIC: INSULIN PENS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 123 ASIA PACIFIC: INSULIN PUMPS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 124 ASIA PACIFIC: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 125 ASIA PACIFIC: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.5 REST OF THE WORLD
    • 8.5.1 REST OF THE WORLD: RECESSION IMPACT
      • 8.5.1.1 Increasing diabetic population to propel market
    • FIGURE 38 AFRICA: TOP FIVE COUNTRIES WITH HIGHEST NUMBER OF DIABETICS (20-79 YEARS)
      • 8.5.1.2 Favorable government policies and increasing prevalence of diabetic population to drive market
    • FIGURE 39 COUNT OF DIABETICS (20-79 YEARS) IN LATIN AMERICA REGION: TOP FIVE COUNTRIES
    • TABLE 126 REST OF THE WORLD: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 127 REST OF THE WORLD: INSULIN PENS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 128 REST OF THE WORLD: INSULIN PUMPS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 129 REST OF THE WORLD: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 130 REST OF THE WORLD: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)

9 COMPETITIVE LANDSCAPE

  • 9.1 OVERVIEW
  • 9.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
    • TABLE 131 INSULIN DELIVERY DEVICES MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
  • 9.3 MARKET SHARE ANALYSIS
    • FIGURE 40 MARKET SHARE ANALYSIS FOR INSULIN PENS, BY KEY PLAYERS, 2022
    • FIGURE 41 MARKET SHARE ANALYSIS FOR INSULIN PUMPS, BY KEY PLAYERS, 2022
    • FIGURE 42 MARKET SHARE ANALYSIS FOR INSULIN PEN NEEDLES, BY KEY PLAYERS, 2022
    • FIGURE 43 MARKET SHARE ANALYSIS FOR INSULIN SYRINGES, BY KEY PLAYERS, 2022
  • 9.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 44 REVENUE ANALYSIS OF KEY PLAYERS (2020-2022)
  • 9.5 MARKET RANKING ANALYSIS
    • FIGURE 45 INSULIN DELIVERY DEVICES MARKET RANKING, BY KEY PLAYERS, 2022
  • 9.6 COMPANY EVALUATION QUADRANT: KEY PLAYERS
    • 9.6.1 STARS
    • 9.6.2 EMERGING LEADERS
    • 9.6.3 PERVASIVE PLAYERS
    • 9.6.4 PARTICIPANTS
    • FIGURE 46 INSULIN DELIVERY DEVICES MARKET: COMPETITIVE LEADERSHIP MAPPING (2022)
  • 9.7 COMPANY EVALUATION QUADRANT: START-UPS & SMES
    • 9.7.1 PROGRESSIVE COMPANIES
    • 9.7.2 DYNAMIC COMPANIES
    • 9.7.3 STARTING BLOCKS
    • 9.7.4 RESPONSIVE COMPANIES
    • FIGURE 47 INSULIN DELIVERY DEVICES MARKET: COMPANY EVALUATION MATRIX FOR START-UPS (2022)
  • 9.8 COMPANY FOOTPRINT OF PLAYERS IN INSULIN DELIVERY DEVICES MARKET
    • TABLE 132 INSULIN DELIVERY DEVICES MARKET: COMPANY FOOTPRINT (2022)
    • 9.8.1 TYPE FOOTPRINT
    • TABLE 133 INSULIN DELIVERY DEVICES MARKET: TYPE FOOTPRINT (2022)
    • 9.8.2 REGIONAL FOOTPRINT
    • TABLE 134 INSULIN DELIVERY DEVICES MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS (2022)
  • 9.9 COMPETITIVE SCENARIO
    • 9.9.1 PRODUCT LAUNCHES
    • TABLE 135 PRODUCT LAUNCHES, JANUARY 2019-JUNE 2023
    • 9.9.2 DEALS
    • TABLE 136 DEALS, JANUARY 2019-JUNE 2023
    • 9.9.3 OTHER DEVELOPMENTS
    • TABLE 137 OTHER DEVELOPMENTS, JANUARY 2019-JUNE 2023

10 COMPANY PROFILES

  • 10.1 KEY PLAYERS
  • (Business Overview, Products/Solutions/Services offered, Recent Developments, MnM View)**
    • 10.1.1 EMBECTA CORP. (FORMERLY BECTON, DICKINSON AND COMPANY DIABETES CARE BUSINESS)
    • TABLE 138 EMBECTA CORP.: COMPANY OVERVIEW
    • FIGURE 48 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
    • 10.1.2 NOVO NORDISK A/S
    • TABLE 139 NOVO NORDISK A/S: COMPANY OVERVIEW
    • FIGURE 49 NOVO NORDISK A/S: COMPANY SNAPSHOT (2022)
    • 10.1.3 MEDTRONIC PLC
    • TABLE 140 MEDTRONIC PLC: COMPANY OVERVIEW
    • FIGURE 50 MEDTRONIC PLC: COMPANY SNAPSHOT (2022)
    • 10.1.4 SANOFI
    • TABLE 141 SANOFI: COMPANY OVERVIEW
    • FIGURE 51 SANOFI: COMPANY SNAPSHOT (2022)
    • 10.1.5 LILLY
    • TABLE 142 LILLY: COMPANY OVERVIEW
    • FIGURE 52 LILLY: COMPANY SNAPSHOT (2022)
    • 10.1.6 YPSOMED HOLDING AG
    • TABLE 143 YPSOMED HOLDING AG: COMPANY OVERVIEW
    • FIGURE 53 YPSOMED HOLDING AG: COMPANY SNAPSHOT (2023)
    • 10.1.7 TANDEM DIABETES CARE, INC.
    • TABLE 144 TANDEM DIABETES CARE, INC.: COMPANY OVERVIEW
    • FIGURE 54 TANDEM DIABETES CARE, INC.: COMPANY SNAPSHOT (2022)
    • 10.1.8 INSULET CORPORATION
    • TABLE 145 INSULET CORPORATION: COMPANY OVERVIEW
    • FIGURE 55 INSULET CORPORATION: COMPANY SNAPSHOT (2022)
    • 10.1.9 BIOCON LIMITED
    • TABLE 146 BIOCON LIMITED: COMPANY OVERVIEW
    • FIGURE 56 BIOCON LIMITED: COMPANY SNAPSHOT (2022)
    • 10.1.10 ROCHE DIABETES CARE
    • TABLE 147 F. HOFFMANN-LA ROCHE: COMPANY OVERVIEW
    • FIGURE 57 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2022)
    • 10.1.11 OWEN MUMFORD
    • TABLE 148 OWEN MUMFORD: COMPANY OVERVIEW
    • 10.1.12 MEDTRUM TECHNOLOGIES INC.
    • TABLE 149 MEDTRUM TECHNOLOGIES INC.: COMPANY OVERVIEW
    • 10.1.13 TERUMO CORPORATION
    • TABLE 150 TERUMO CORPORATION: COMPANY OVERVIEW
    • FIGURE 58 TERUMO CORPORATION: COMPANY SNAPSHOT (2021)
    • 10.1.14 WOCKHARDT
    • TABLE 151 WOCKHARDT: COMPANY OVERVIEW
    • FIGURE 59 WOCKHARDT: COMPANY SNAPSHOT (2021)
  • *Details on Business Overview, Products/Solutions/Services offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
  • 10.2 OTHER PLAYERS
    • 10.2.1 CEQUR CORPORATION
    • 10.2.2 EOFLOW CO., LTD.
    • 10.2.3 HINDUSTAN SYRINGES & MEDICAL DEVICES LTD
    • 10.2.4 SOOIL DEVELOPMENTS CO., LTD
    • 10.2.5 SUNGSHIM MEDICAL CO., LTD.
    • 10.2.6 VICENTRA B.V.
    • 10.2.7 DEBIOTECH SA
    • 10.2.8 JIANGSU DELFU MEDICAL DEVICE CO., LTD
    • 10.2.9 HASELMEIER
    • 10.2.10 MANNKIND CORPORATION
    • 10.2.11 HTL-STREFA S.A.

11 APPENDIX

  • 11.1 DISCUSSION GUIDE
  • 11.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 11.3 CUSTOMIZATION OPTIONS
  • 11.4 RELATED REPORTS
  • 11.5 AUTHOR DETAILS